Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 7/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238022 | 0.91 | KMT2A (0.41) | RAB9ANPC1KMT2AMEN1ALOX12 | |
| SCHEMBL4236831 | 0.90 | RAB9A (0.50) | RAB9ANPC1KMT2AMEN1ALOX12 | |
| SCHEMBL4510231 | 0.89 | KMT2A (0.43) | RAB9ANPC1KMT2AMEN1ALOX12 | |
| SCHEMBL4233527 | 0.86 | KDR (0.40) | HRH3MET | |
| SCHEMBL4238872 | 0.85 | P2RX3 (0.39) | P2RX3MET | |
| SCHEMBL5338964 | 0.84 | KMT2A (0.45) | RAB9ANPC1KMT2AMEN1ALOX12 | |
| SCHEMBL4503291 | 0.84 | KMT2A (0.45) | RAB9ANPC1KMT2AMEN1ALOX12 | |
| SCHEMBL4240270 | 0.83 | RAB9A (0.41) | RAB9ANPC1KMT2AMEN1ALOX12 | |
| SCHEMBL4238865 | 0.83 | GABRP (0.41) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL4232416 | 0.83 | HSPB1 (0.36) | RAB9AHSPB1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | claimed |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| WO-2007042878-A1 | NOVEL HETEROCYCLIC ANALOGS OF BIPHENYL ETHERS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | UGT2B7, CYP4B1, CYP1B1 | RAB9A 1148/4885NPC1 633/4885KMT2A 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.